Drogheda expelled from Europe after losing CAS appeal
Drogheda United's appeal against their dismissal from the 2025-26 Uefa Conference League has been rejected by the Court of Arbitration for Sport (CAS).
The Irish Premier Division club were expelled by Uefa under a rule which states two clubs in the same competition cannot be under the same ownership, with US-based Trivela Group also owning Danish side Silkeborg.
Advertisement
Uefa rules mean the lower-ranked team, in this case Drogheda, are excluded from the competition.
Drogheda won the FAI Cup in November 2024 as a semi-professional side. However, Silkeborg's seventh-place finish in the Danish league outweighs Drogheda's ninth place in the League of Ireland Premier Division.
In a statement, Drogheda expressed their "great heartbreak and disbelief" at CAS' decision.
"We strongly disagree with this decision, and had hoped and believed that the principles of fairness and common sense would prevail," the club said.
"After months of engagement, constructive dialogue, countless hours of legal preparation, and multiple proposals based on frameworks that have been accepted in the past, we have come up short.
"Despite genuine and vocal support across the football world, the ruling did not fall in our favour. We are heartbroken by the outcome."
More to follow.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
SoftBank Sells T-Mobile Stake for $4.8 Billion to Fund AI Push
(Bloomberg) -- SoftBank Group Corp. raised around $4.8 billion through a sale of T-Mobile US Inc. shares, a move that helps fund the Japanese company's grandiose plans for artificial intelligence. As Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention Space Security Concerns Hit Some of the World's 'Most Livable Cities' As American Architects Gather in Boston, Retrofits Are All the Rage The Tokyo-based technology group sold 21.5 million T-Mobile shares for $224 each — pricing at the bottom of the $224 to $228 range — in an unregistered overnight block sale, according to the final terms of the deal seen by Bloomberg News. The offering — which Bloomberg reported earlier — represents a discount of 3% to T-Mobile US's Monday closing price of $230.99 per share. SoftBank is ramping up investments aimed at making AI reasoning superior to humans': It plans to put down as much as $30 billion in OpenAI and is also working with the ChatGPT creator to ferry hundreds of billions of dollars into data centers and related infrastructure in the US and around the world. Its original plans for debt financing had snagged on uncertainties around US tariffs. T-Mobile shares fell 3.9% in extended trading. They have climbed 4.7% in the year to date through Monday's close. SoftBank's shares climbed as much as 2.3% in early trading in Tokyo. The deal is the biggest US share sale since Toronto-Dominion Bank sold a $13.1 billion stake in brokerage firm Charles Schwab Corp. in February. Sales of new and existing shares in US-listed companies reached $91.4 billion in the year to date, up from $75.9 billion in the same period a year ago, data compiled by Bloomberg show. The T-Mobile stake sale would be the latest example of SoftBank founder Masayoshi Son tapping past investment successes — such as an early bet on Alibaba Group Holding Ltd. that's yielded thousands-fold returns — to fund new ventures. SoftBank received T-Mobile shares with the completion of the US telecom company's $26.5 billion acquisition of Sprint Corp. in April 2020. Later that year, SoftBank substantially reduced its stake in T-Mobile via a $21 billion deal that helped pay for a record buyback of SoftBank's shares. The stake offered represents about 1.9% of T-Mobile's outstanding shares, according to Bloomberg calculations. SoftBank owned 85.4 million shares or 7.5% of T-Mobile as of March 31, according to its annual report. Deutsche Telekom AG is T-Mobile's largest shareholder with a 59% stake, according to a June 12 filing with the US Securities and Exchange Commission. Bank of America Corp. was sole bookrunner for the deal, the terms show. --With assistance from Min Jeong Lee. (Updates share reaction and adds background from the first paragraph.) Ken Griffin on Trump, Harvard and Why Novice Investors Won't Beat the Pros American Mid: Hampton Inn's Good-Enough Formula for World Domination How a Tiny Middleman Could Access Two-Factor Login Codes From Tech Giants The Spying Scandal Rocking the World of HR Software US Allies and Adversaries Are Dodging Trump's Tariff Threats ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
AFYREN Begins New Phase of Industrial Strategy as First Plant AFYREN NEOXY Achieves Continuous Production
AFYREN NEOXY: continuous production achieved and acceleration in commercialization Industrial continuous running1 of all stages of the process validated in recent weeks and start of industrial ramp-up Hundreds of tons of bio-based acids produced and currently being commercialized €165 million in revenue secured by contracts, to be executed in coming years Update on short and medium-term objectives AFYREN NEOXY: objective to achieve significant production revenue in 2025, estimated in the low single-digit million euros range2, and plant break-even3 targeted within a few quarters AFYREN: aims to achieve the goal of building and operating three plants in a sequence manner to better capitalize on the success of AFYREN NEOXY, including intermediary debottlenecking project4 CLERMONT-FERRAND, France & LYON, France, June 17, 2025--(BUSINESS WIRE)--Regulatory News: AFYREN (Paris:ALAFY), a greentech company offering industrial customers bio-based, low-carbon products through its unique fermentation technology based on a circular model, today announced its first plant AFYREN NEOXY has achieved continuous production, enabling the acceleration of commercialization. Nicolas SORDET, CEO AFYREN, declares: "The transition to continuous production at AFYREN NEOXY, the first biorefinery using the AFYREN technology, demonstrates our command of all key stages of an innovative process with no equivalents worldwide. This major success marks the end of an especially demanding period for our teams, whose dedication and resilience I sincerely commend. We are now in the industrial ramp-up phase, enabling us to regularly deliver finished products to our customers in increasing volumes. Building on this success, we are planning to increase our industrial capacity production gradually in coming quarters, in order to better capitalize on AFYREN NEOXY." Continuous production achieved and acceleration in commercialization AFYREN has successfully manufactured hundreds of tons of products in recent weeks, resulting from continuous production at the plant. The bio-based acids produced are currently undergoing qualification prior to delivery, in accordance with the multi-year contracts signed with customers. This major milestone is the culmination of two years of efforts by the AFYREN and AFYREN NEOXY teams to ensure the reliability of the equipment and mastering the operating conditions at industrial scale, ensuring the continuous operation of this unique biorefinery. This milestone marks the beginning of a new phase that will see the gradual ramp-up of AFYREN NEOXY's industrial production to ultimately achieve the targets set in 2021: annual production revenue of around €35 million with a current EBITDA margin of around 25% (equivalent to a current EBITDA of around €9 million) at full capacity (16,000 tons per year). During the ramp-up period, product shipment will be made on a regular basis with priority given to long-term customers. As a reminder, commercial commitments secured through contracts represent cumulative revenue of over €165 million, to be recognized in the upcoming years. These contracts are with leading players in the target markets of human nutrition and feed, flavors and fragrances, life sciences, materials sciences, and lubricants. Update on short and medium-term objectives On this basis, AFYREN NEOXY expects production revenue in 2025 to be in the low single-digit million euros range5. The plant is expected to break even (positive current EBITDA) within a few quarters. In parallel, AFYREN is planning targeted investments to lift bottlenecks6 at the AFYREN NEOXY plant. By doing so, AFYREN would increase production capacity and boost target profitability beyond the previously mentioned objectives. AFYREN's medium-term objectives will be updated to reflect the progress of the AFYREN NEOXY ramp-up. The core operational and financial targets remain unchanged — specifically the plan to build and operate three production sites, generating a combined €150 million in revenue at full capacity7 with a target Group EBITDA margin of around 30%. Instead of adhering strictly to the current target of having three plants installed, of which two in continuous production by 2028, AFYREN is exploring a phased approach. This would allow the company to consolidate the achievements of its first biorefinery and leverage the operational experience gained before moving forward with the development of Plants 2 and 3. This approach will enable the Group to maintain a safe degree of agility and keep good control of AFYREN's cash burn and should enable the financing of future plants under optimized conditions. Stefan BORGAS, Chairman of AFYREN's Board of Directors, added: "The transition to continuous production is a major milestone in AFYREN's history. The Company is joining a very select group of companies that have successfully industrialized a competitive green technology. This is a remarkable achievement in the increasingly demanding and selective chemical industry. It opens up extremely positive prospects for our company in terms of industrial and commercial development." About AFYREN AFYREN is a French greentech company, founded in 2012, focused on providing innovative, sustainable solutions to reduce reliance on fossil-based resources. AFYREN's proprietary, nature-inspired fermentation technology valorizes local biomass from non-food agricultural co-products to produce 100% biobased, low-carbon carboxylic acids. The company's sustainable solutions address decarbonization challenges in a wide variety of strategic sectors, including human and animal nutrition, flavors and fragrances, life sciences, materials science, plus lubricants and technical fluids. AFYREN's competitive, plug-and-play, circular technology enables manufacturers to adopt sustainable solutions without modifying production processes. The company's first industrial plant, AFYREN NEOXY, a joint venture with Bpifrance's SPI fund, is based in the Grand-Est region of France, serving primarily the European market. AFYREN is also pursuing a project in Thailand with a global leader in the sugar industry and is building its presence in the Americas, based on existing distribution agreements. At the end of 2024, AFYREN employed 130 people across sites in Lyon, Clermont-Ferrand and Carling Saint-Avold. Committed to continuous innovation, the company invests 20% of its annual budget in R&D to further develop the range of sustainable solutions. AFYREN is listed on Euronext Growth® Paris since 2021 (ISIN code: FR0014005AC9, ticker: ALAFY). For more information, visit and follow us on LinkedIn. Financial calendar Events Dates Annual General Meeting Tuesday, June 17, 2025, in Lyon 2025 half-year results Thursday, September 25, 2025 1 Simultaneous operation of all stages of the process – from fermentation to finished products, in a stable and repeatable manner2 Projections subject to operational adjustments to be made to increase production rates during the ramp-up phase3 Positive current EBITDA from production4 Removal of capacity bottlenecks identified in the operations chain, enabling increased production capacity and reliability of operations with a higher target profitability for AFYREN NEOXY5 Projections subject to operational adjustments to be made to increase production rates during the ramp-up phase6 Removal of capacity bottlenecks identified in the operations chain, enabling increased production capacity and reliability of operations with a higher target profitability for AFYREN NEOXY7 After a ramp-up period View source version on Contacts AFYRENDirector for ESG, Communications and Public AffairsCaroline Investor RelationsMark Reinhardinvest@ NewCapInvestor RelationsThéo Martin / Mathilde BohinTel: +33 1 44 71 94 94afyren@ Media RelationsNicolas Mérigeau / Gaëlle FromaigeatTel: +33 1 44 71 94 98afyren@ MC Services AG (international)Investor RelationsBettina EllinghorstMedia RelationsShaun Brown, Dr. Johanna KoblerTel: +49 89 210 228 0afyren@ Sign in to access your portfolio
Business Wire
2 hours ago
- Business Wire
Faraday Future Announces Additional Senior Leadership Entering Into 10b5-1 Stock Purchase Plans
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ('Faraday Future', 'FF' or the 'Company'), a California-based global shared intelligent electric mobility ecosystem company, today announced that a number of its senior leadership have entered into 10b5-1 executive stock purchase plans. Under SEC compliance rules, there will be either a 45 or 90-day cooling-off period, after which their broker will automatically execute the stock purchases at times and in amounts in accordance with the plans. A combined total of $60,000 worth of share purchase commitments for FF common stock (including commission fee) were made by various members of FF's leadership team, including Koti Meka, FF CFO, Xiao (Max) Ma, FX brand CEO and Dr. Lei Gu, President of FX Global EV R&D Center. The 10b5-1 plans were officially initiated on June 13, 2025. 'These planned stock purchases reflect the continued confidence by members of FF's core leadership team and serve as a positive indicator by all of them in FF's long-term vision and commitment to our mission and products,' said YT Jia, FF Founder and Global Co-CEO. 'This is yet another demonstration of our core principle: Stockholders First.' ABOUT FARADAY FUTURE Faraday Future is a California-based global shared intelligent electric mobility ecosystem company. Founded in 2014, the Company's mission is to disrupt the automotive industry by creating a user-centric, technology-first, and smart driving experience. Faraday Future's flagship model, the FF91, exemplifies its vision for luxury, innovation, and performance. The FX strategy aims to introduce mass production models equipped with state-of-the-art luxury technology similar to the FF 91, targeting a broader market with middle-to-low price range offerings. FF is committed to redefining mobility through AI innovation. Join us in shaping the future of intelligent transportation. For more information, please visit FORWARD LOOKING STATEMENTS This press release includes 'forward looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words 'plan to,' 'can,' 'will,' 'should,' 'future,' 'potential,' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding 10b5-1 purchase plans, are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, among others: each executive's ability to cancel or amend his 10b5-1 purchase plan; potential volume limitations under Rule 144 or Rule 145 of the Securities Act of 1933, as amended, or Regulation M; the possible suspension of purchases due to a trading suspension, legal, regulatory or contractual restrictions; or a subsequent determination that a 10b5-1 plan does not comply with Rule 10b5-1 or other applicable securities laws. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of the Company's Form 10-K filed with the SEC on March 31, 2025, and other documents filed by the Company from time to time with the SEC.
